Eskayef produces COVID-19 drug Remdesivir for 1st time in country
Published: 08:07 PM, 8 May 2020 Updated: 08:14 PM, 8 May 2020
Eskayef Pharmaceuticals Ltd., a reputed pharmaceutical company of the country, has completed the production of Remdesivir, the medicine that treats coronavirus patients, developed by Gilead Sciences, a US-based company and the preparations for marketing have already started from Friday morning, confirmed Simeen Hossain, Managing Director and CEO of the pharmaceutical company.
“At this juncture in the country’s COVID-19 situation, we want to give the good news to the people that we have completed all the steps to produce generic remediation of Remdesivir, the only effective drug against the virus in the world,” she said.
The U.S. Food and Drug Administration (FDA) last week approved the use of Remdesivir as a COVID-19 drug. The Japanese Drug Administration has allowed the drug to be administered to the patients since May 7.
Simeen Hossain said the drug administration permitted the use of the drug last March. Soon after the approval of the drug administration, our formulation scientists started working on Remdesivir from mid-March.
“Since it is an intravenous injection, a delicate process has to be followed in its production. It has been possible to produce in such a short time due to the relentless work of Eskayef personnel for two months.”
We have ensured adequate raw material availability by contracting with the suppliers of the main ingredients of the medicine, said the Managing Director and CEO of Eskayef.
Remdesivir has so far shown the highest efficacy against coronavirus or COVID-19 disease.
Gilead’s experiments have shown that the use of this drug has improved the condition of patients. These drugs are to be injected into human veins. Its dose depends on the severity of the disease. Severely ill patients may need a 5- or 10-day dose.
Gilead owns the exclusive production of Remdesivir, however, under international trade law, least developed countries, such as the UN-recognized Bangladesh, may revoke these patents. As a result, these countries can produce drugs at affordable prices.
However, this drug is not currently available in the open market. It will be given to the government-approved hospitals or clinics that treat coronavirus patients.